How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

8,360 results for

Skin Conditions in Diabetes Mellitus

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Purified Anthocyanins Supplementation in Type 2 Diabetes Mellitus

Party): Di Li, Sun Yat-sen University Study Details Study Description Go to Brief Summary: Anthocyanins, the water-soluble compounds that make plants appear different colors, have been shown to prevent insulin resistance, reduce the blood glucose and oxidative stress in rodents. The purpose of our study is to evaluate a potential protective effect of purified anthocyanins supplement on type 2 diabetes mellitus patients. Condition or disease Intervention/treatment Phase Diabetes Mellitus,Type 2 (...) Volunteers: No Criteria Inclusion Criteria: Subject is diagnosed with type 2 diabetes mellitus according to the Chinese type 2 diabetes prevention guide 2010, diagnostic criteria are as follows:(1) Diabetes symptoms (polydipsia, polyphagia, polyuria, weight loss, skin itching, blurred vision and other acute metabolic network disorder that caused by high blood sugar)combined with random blood sugar ≥11.1 OR,(2)fasting plasma glucose(FPG)≥7.0 OR (3)2h blood sugar after oral glucose tolerance test(OGTT

2014 Clinical Trials

162. A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

and injectable medications that only reduce blood sugar (glucose) when it is high. The other strategy is based on non-glucose dependent agents. The trial will last up to 72 weeks for each participant. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 2 Drug: Glimepiride Drug: Metformin Drug: Pioglitazone Drug: Acarbose Drug: Linagliptin Drug: Sitagliptin Drug: Liraglutide Drug: Insulin Glargine Drug: Exenatide once weekly (QW) Drug: Exenatide twice daily (BID) Phase 4 Study Design Go (...) A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2014 Clinical Trials

163. Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006)

objective will be tested for both 5-mg and 15-mg doses of ertugliflozin. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: Ertugliflozin 5 mg Drug: Ertugliflozin 15 mg Drug: Placebo for ertugliflozin 5 mg Drug: Metformin Drug: Sitagliptin Drug: Glimepiride Biological: Insulin Drug: Placebo for ertugliflozin 10 mg Phase 3 Detailed Description: The duration of the trial will be approximately 69 weeks. This will include a 1-week Screening Period, an up to 12-week wash-off (...) Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006) Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration

2014 Clinical Trials

164. Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)

) of enteric coated (EC) darapladib, will specifically reduce the number of macrophages and/or result in a higher proportion of M2 macrophages in skin blisters induced by cantharidin (a chemical agent that causes blisters). In Part A of the study, a cohort of 8 subjects with type 2 diabetes mellitus will be recruited. In Part B of the study, a cohort of 8 additional healthy subjects with matching age (+/- 24 months) and gender to Part A may be recruited. Condition or disease Intervention/treatment Phase (...) , 2017 Last Verified: May 2017 Keywords provided by GlaxoSmithKline: cellular accumulation macrophage phenotype cantharidin blister M1/M2 inflammatory mediators Type 2 diabetes mellitus darapladib cytokines Additional relevant MeSH terms: Layout table for MeSH terms Diabetes Mellitus Diabetes Mellitus, Type 2 Atherosclerosis Blister Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Cardiovascular Diseases Skin

2014 Clinical Trials

165. The Safety and Efficacy of MK-1293 Versus Lantusâ„¢ in Participants With Type 2 Diabetes Mellitus (MK-1293-006)

%) in participants treated with MK-1293 compared with that in participants treated with Lantus™. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: MK-1293 Drug: Lantus™ Drug: Prandial insulin Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 531 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Phase III (...) The Safety and Efficacy of MK-1293 Versus Lantusâ„¢ in Participants With Type 2 Diabetes Mellitus (MK-1293-006) The Safety and Efficacy of MK-1293 Versus Lantus™ in Participants With Type 2 Diabetes Mellitus (MK-1293-006) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2014 Clinical Trials

166. A Study of the Safety and Efficacy of MK-1293 Compared to Lantusâ„¢ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003)

baseline is non-inferior in participants treated with MK-1293 compared with participants treated with Lantus™. Condition or disease Intervention/treatment Phase Type 1 Diabetes Mellitus Drug: MK-1293 Drug: Lantus™ Drug: Prandial Insulin Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 508 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official (...) A Study of the Safety and Efficacy of MK-1293 Compared to Lantusâ„¢ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003) A Study of the Safety and Efficacy of MK-1293 Compared to Lantus™ in Participants With Type 1 Diabetes Mellitus (T1DM) (MK-1293-003) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You

2014 Clinical Trials

167. An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets Within the Bioartificial Pancreas Beta-Air in Patients With Type 1 Diabetes Mellitus

episodes. Condition or disease Intervention/treatment Phase Long-standing Type 1 Diabetes Mellitus Device: Beta-Air device for encapsulation of transplanted human islets Phase 1 Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 4 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: An Open Label, Pilot Investigation, to Assess the Safety and Efficacy (...) An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets Within the Bioartificial Pancreas Beta-Air in Patients With Type 1 Diabetes Mellitus An Open Label, Pilot Investigation, to Assess the Safety and Efficacy of Transplantation of Macro-encapsulated Human Islets Within the Bioartificial Pancreas Beta-Air in Patients With Type 1 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record

2014 Clinical Trials

168. A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477

, neurological, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, infectious, connective tissue or inflammatory diseases, and any type of cancer (with the exception of treated basal cell carcinoma of the skin) or other clinically significant disease Use of anti-diabetic drugs other than metformin or sulfonylureas within 2 months prior to screening Any condition or disease detected during the medical interview / physical examination that would render the patient unsuitable (...) A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477 A Study to Investigate in Healthy Volunteers (Part 1) and in Patients With Type 2 Diabetes Mellitus (Part 2) the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of RO6799477 - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer

2014 Clinical Trials

169. A Prospective Observational Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus

optimization of the product.) First Posted : June 6, 2014 Last Update Posted : July 26, 2016 Sponsor: CeQur Corporation Information provided by (Responsible Party): CeQur Corporation Study Details Study Description Go to Brief Summary: The purpose of the study is to obtain an assessment (efficacy, safety, and patient reported outcomes) of basal bolus insulin delivery with PaQ in insulin-using patients with type 2 diabetes mellitus (T2DM). Condition or disease Intervention/treatment Type 2 Diabetes Mellitus (...) A Prospective Observational Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus A Prospective Observational Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2014 Clinical Trials

170. A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

of ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on metformin monotherapy. The primary study hypothesis is that at Week 26, the mean reduction from baseline in hemoglobin A1c (HbA1c) for ertugliflozin is greater than that for placebo. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: Ertugliflozin 5 mg Drug: Ertugliflozin 15 mg Drug: Placebo to Ertugliflozin Other: Glimepiride Drug: Placebo to Glimepiride Biological: Basal (...) A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007). A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007). - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results

2014 Clinical Trials

171. High prevalence of cutaneous manifestations in the elderly with diabetes mellitus: an institution-based cross-sectional study in Taiwan. (PubMed)

risks of bacterial infection, scabies, or skin tags.The DM-associated cutaneous manifestations were chronic ulcers, brown spots on the legs, and pruritus. By observing clues of diabetic cutaneous features, a more complete condition of diabetic patients can be appreciated. The information is essential for providing appropriate treatment and key nursing points regarding the diabetes-associated skin diseases.© 2014 European Academy of Dermatology and Venereology. (...) High prevalence of cutaneous manifestations in the elderly with diabetes mellitus: an institution-based cross-sectional study in Taiwan. Diabetes mellitus (DM) is a common endocrine disorder and an increasing epidemic worldwide. Proportional diabetic patients eventually develop cutaneous diseases.This study determined the statistical association of cutaneous manifestations and DM as well as the DM-associated cutaneous manifestations in elderly male residents.A cross-sectional study

2014 Journal of the European Academy of Dermatology and Venereology

172. Effects of Berberine Hydrochloride and Bifidobacterium in Diabetes Mellitus Prevention and Treatment

Posted : March 11, 2014 Last Update Posted : November 14, 2018 Sponsor: Xijing Hospital Information provided by (Responsible Party): Xijing Hospital Study Details Study Description Go to Brief Summary: The aim of this study is to assess the beneficial effects of Bifidobacterium Hydrochloride and Berberine on lowering glucose in patients with type 2 diabetes mellitus and to detect the potential mechanism. Condition or disease Intervention/treatment Phase Type 2 Diabetes Mellitus Drug: Bifidobacterium (...) Effects of Berberine Hydrochloride and Bifidobacterium in Diabetes Mellitus Prevention and Treatment Effects of Berberine Hydrochloride and Bifidobacterium in Diabetes Mellitus Prevention and Treatment - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2014 Clinical Trials

173. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections

Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections We use cookies to enhance your experience on our website. By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America | Clinical Infectious Diseases | Oxford Academic Search Account Menu Menu Navbar (...) Search Filter Mobile Microsite Search Term Close search filter search input Article Navigation Close mobile search navigation Article navigation 15 July 2014 Article Contents Article Navigation Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America Dennis L. Stevens 1Division of Infectious Diseases, Department of Veterans Affairs, Boise, Idaho Search for other works by this author on: Alan L. Bisno 2Medical

Full Text available with Trip Pro

2014 Infectious Diseases Society of America

174. Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers

Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers Safety and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Safety (...) and Efficacy of Vasculera® in the Healing of Diabetic Skin Ulcers The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02361437 Recruitment Status : Terminated (Investigator's hospital sold and study cancelled) First Posted : February 11, 2015 Last Update Posted : December 13, 2017 Sponsor: Primus

2015 Clinical Trials

175. Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition

of uncontrolled diseases, such as thyroidal dysfunction, angina pectoralis, serious cardiac arrhythmias, serious heart failure, neuropsychiatric infection or disease. Patients with controlled and uncontrolled diabetes mellitus Patients with Uncontrolled hypertension will be excluded. Immunocompromised patients will be excluded from participating the study Patients with known positivity for human immunodeficiency virus (HIV), HBsAg and HCV. Positive results for drugs of abuse (benzodiazepines, opioids (...) Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved

2018 Clinical Trials

176. A Single-Center Open-Label Study of 1064 nm Nd:YAG for Nonablative Skin Rejuvenation

Last Update Posted : February 5, 2018 See Sponsor: Cutera Inc. Information provided by (Responsible Party): Cutera Inc. Study Details Study Description Go to Brief Summary: The purpose of this investigation is to evaluate the safety and efficacy of the Cutera excel V Laser Genesis procedure utilizing the 1064nm Nd:YAG laser for skin rejuvenation. Condition or disease Intervention/treatment Phase Skin Pigment Photoaging Device: excel V Laser Not Applicable Detailed Description: This is a single (...) , wounds, scars, large moles. Pregnant and/or breastfeeding. Having an infection, dermatitis or a rash in the treatment area. Significant concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., uncontrolled hypertension. Suffering from coagulation disorders, or taking prescription anticoagulation medication which might make study participation unsafe according to Investigator's discretion. History of keloid scarring, hypertrophic scarring or of abnormal wound healing. History

2018 Clinical Trials

177. Phase 1 Study of HF-LED-RL in Fitzpatrick Skin Types I to III

/ethnicity Nondominant proximal anterior forearm is wide enough to ensure reproducible placement of LED-RL phototherapy or mock therapy hand-held unit Available and willing to attend all clinic visits Able and willing to give informed consent Exclusion Criteria: Subjects using any photosensitizers (i.e. lithium, melatonin, phenothiazine antipsychotics, antibiotics) Subjects with diabetes mellitus (DM) Subjects with a history of skin cancer. Subjects with systemic lupus erythematous (SLE) Subjects (...) . Condition or disease Intervention/treatment Phase Skin Diseases Keloid Scar Fibrosis Hypertrophic Skin Device: HF-LED-RL Phototherapy Device: Mock Therapy Phase 1 Detailed Description: The effects of visible light, while common in the environment (visible spectrum accounts for 44% of total solar energy), remain undefined. An important safety feature of visible red light (600 nm to 700 nm) is that it does not generate pro-carcinogenic DNA damage as does ultraviolet (UV) light. Recently published clinical

2018 Clinical Trials

178. The Nail Flag Sign: Case Report in a Man with Diverticulitis and Review of Dermatology Flag Sign of the Hair, Skin, and Nails (PubMed)

The Nail Flag Sign: Case Report in a Man with Diverticulitis and Review of Dermatology Flag Sign of the Hair, Skin, and Nails A sign is a physical feature or microscopic change which can be observed when the patient or their tissue specimen is evaluated. An astute clinician or pathologist may be able to diagnose a patient's condition by recognizing this unique morphologic feature or pathological change. In dermatology, the flag sign-alternating transverse bands of the skin or its adnexal (...) in actinic keratosis, and demonstrates by alternating parakeratosis and orthokeratosis of the stratum corneum-corresponding to the type of hyperkeratosis occurring above the interadnexal epidermis or the ostea of the acrosyringia and acrotrichia. The nail flag sign-noted in some individuals who have diabetes mellitus, diverticulitis, leprosy, or vitiligo-presents with alternating white and pink-red horizontal bands beginning at the proximal nail fold and extending distally to the free edge of the nail

Full Text available with Trip Pro

2018 Cureus

179. Simple Continuous, Subcuticular and Interrupted Skin Suturing of Episiotomy and 2nd-degree Perineal Tears

susceptible to injury, either through accidental injury or planned surgical incision. Today, as surgery increases in complexity, and the heightened public awareness of scar cosmesis and skin healing need to be optimized to ensure the overall success of the surgical procedure Condition or disease Intervention/treatment Phase Episiotomy Wound Procedure: Episiotomy Not Applicable Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 138 (...) . For general information, Layout table for eligibility information Ages Eligible for Study: Child, Adult, Older Adult Sexes Eligible for Study: Female Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Normal vaginal delivery. At term (37 40 weeks ). Live baby. Vertex presentation Exclusion Criteria: Third and fourth degree perineal tear. Instrumental vaginal delivery. Previous perineal surgery. Anaemia with hemoglobin level < 9 g/dl. Diabetes mellitus. Coagulation abnormalities. Postpartum

2018 Clinical Trials

180. To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin

therapy History of active hair loss due to alopecia areata, scarring alopecia, diffuse telogen effluvium or conditions other than androgenetic alopecia Immunological disorders such as alopecia areata, and systemic lupus erythematosus and other systemic known autoimmune disorders Diabetes mellitus Coagulation deficiencies Topical treatments for hair growth (minoxidil, anti-androgens or other agents known to affect hair growth) in the last 6 months Topical treatments of the scalp including (...) classification Exclusion Criteria: Any dermatological disorders of the scalp which might interfere with the application of Investigational Medical Product or examination method, such as fungal or bacterial infections, seborrheic dermatitis, psoriasis, eczema, folliculitis or scalp atrophy Any skin pathology (e.g. scar, nevus) or general condition (e.g. uncontrolled thyroid diseases) that in the investigator's opinion can interfere with the evaluation of the treatment areas or requires topical or systemic

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>